MARYVILLE NURS 615 PHARM 3 EXAM QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% VERIFIED
SOLUTIONS | UPDATED PER LATEST GUIDELINES | GRADED A+...
Core Domains
Pharmacokinetics and Pharmacodynamics in Special Populations
Pharmacotherapy of Cardiovascular Disorders
Pharmacotherapy of Endocrine and Metabolic Disorders
Pharmacotherapy of Infectious Diseases
Pharmacotherapy of Neurological and Psychiatric Disorders
Pharmacotherapy of Pain and Inflammation
Pharmacotherapy of Respiratory and Gastrointestinal Disorders
Pharmacogenomics and Precision Medicine
Adverse Drug Reactions, Drug Interactions, and Toxicology
Prescriptive Authority, Legal-Ethical Considerations, and Evidence-Based Prescribing
Introduction
This comprehensive assessment evaluates the advanced pharmacotherapeutic knowledge and clinical reasoning
required for graduate-level nursing practice. The examination tests the candidate's ability to apply the principles of
pharmacokinetics, pharmacodynamics, and pharmacogenomics to the safe and effective prescribing of
medications across the lifespan. Using a rigorous multiple-choice and scenario-based format, this assessment
challenges the learner to analyze complex patient cases, interpret laboratory and genetic data, and make
evidence-based clinical decisions regarding drug selection, dosing, and monitoring. Success requires mastery of
,advanced pharmacology, critical thinking, and integration of ethical and legal standards to optimize therapeutic
outcomes and minimize adverse events in diverse patient populations.
SECTION ONE: Questions 1–100
Question 1
A 68-year-old patient with a history of heart failure with reduced ejection fraction (HFrEF) is prescribed
metoprolol succinate. What is the primary mechanism by which this beta-blocker improves morbidity and
mortality in heart failure?
A. Increasing cardiac contractility through beta-1 receptor stimulation.
B. Blocking the toxic effects of excessive sympathetic nervous system activation on the myocardium, thereby
reducing myocardial oxygen demand and preventing cardiac remodeling.
C. Acting as a potent vasodilator to decrease afterload.
D. Directly inhibiting the renin-angiotensin-aldosterone system (RAAS).
🟢 Correct Answer:
B
🔴 RATIONALE:
In HFrEF, chronic activation of the sympathetic nervous system (SNS) leads to elevated levels of catecholamines,
which are directly toxic to the myocardium. They increase heart rate, contractility, and afterload, which worsens
cardiac remodeling and apoptosis. Beta-blockers like metoprolol succinate (a beta-1 selective blocker) inhibit
these toxic effects by blocking cardiac beta-1 receptors. This reduces heart rate, decreases myocardial oxygen
demand, and slows the progression of ventricular remodeling. They do not increase contractility or directly
inhibit the RAAS.
,Question 2
A nurse practitioner is prescribing levothyroxine for a 55-year-old patient newly diagnosed with
hypothyroidism. What is the most important teaching point regarding the timing of administration?
A. "Take this medication with a full meal to prevent gastric irritation."
B. "Take this medication at bedtime to align with your circadian rhythm."
C. "Take this medication on an empty stomach, first thing in the morning, at least 30 to 60 minutes before
breakfast."
D. "Take this medication with a calcium supplement to improve absorption."
🟢 Correct Answer:
C
🔴 RATIONALE:
Levothyroxine absorption is significantly impaired by food, particularly fiber, soy, and certain minerals like
calcium and iron. To achieve consistent, therapeutic blood levels, levothyroxine must be taken on an empty
stomach, ideally first thing in the morning, and the patient must wait 30 to 60 minutes before eating or drinking
anything other than water. Taking it with food or supplements drastically reduces bioavailability and can lead to
inadequate treatment of hypothyroidism.
Question 3
A patient with atrial fibrillation is on long-term warfarin therapy. The provider is considering adding
trimethoprim-sulfamethoxazole (TMP-SMX) for an acute urinary tract infection. What is the primary concern
regarding this drug combination?
A. TMP-SMX decreases the absorption of warfarin, reducing its anticoagulant effect.
B. TMP-SMX is a potent inhibitor of the CYP2C9 enzyme, which metabolizes the S-isomer of warfarin, leading to
a significant increase in the international normalized ratio (INR) and bleeding risk.
, C. Warfarin induces the metabolism of TMP-SMX, rendering the antibiotic ineffective.
D. There is no significant interaction between these two medications.
🟢 Correct Answer:
B
🔴 RATIONALE:
Warfarin is a racemic mixture of R and S isomers, with the S-isomer being 2.5 to 5 times more potent. The S-
isomer is primarily metabolized by the hepatic CYP2C9 enzyme. TMP-SMX is a known, potent inhibitor of
CYP2C9. Co-administration leads to inhibition of warfarin metabolism, causing a rapid and dangerous rise in the
INR and a significant risk of major hemorrhage. If this combination is unavoidable, the warfarin dose must be
preemptively reduced by 20-50% and the INR monitored extremely closely.
Question 4
A 72-year-old patient with chronic renal insufficiency (estimated glomerular filtration rate [eGFR] of 28 mL/min)
requires anticoagulation for a newly diagnosed deep vein thrombosis. The provider selects enoxaparin. What
adjustment to the treatment plan is essential?
A. No adjustment is needed; renal function does not affect enoxaparin dosing.
B. The dose of enoxaparin must be reduced, as low molecular weight heparins are primarily cleared renally and
accumulate in renal impairment, increasing the risk of major bleeding.
C. The frequency of enoxaparin must be increased to twice-daily dosing.
D. Enoxaparin is absolutely contraindicated at any eGFR below 60 mL/min.
🟢 Correct Answer:
B
🔴 RATIONALE:
Low molecular weight heparins (LMWHs) like enoxaparin are cleared primarily by the kidneys. In patients with
significant renal impairment (typically an eGFR less than 30 mL/min), the drug accumulates, leading to a
SOLUTIONS | UPDATED PER LATEST GUIDELINES | GRADED A+...
Core Domains
Pharmacokinetics and Pharmacodynamics in Special Populations
Pharmacotherapy of Cardiovascular Disorders
Pharmacotherapy of Endocrine and Metabolic Disorders
Pharmacotherapy of Infectious Diseases
Pharmacotherapy of Neurological and Psychiatric Disorders
Pharmacotherapy of Pain and Inflammation
Pharmacotherapy of Respiratory and Gastrointestinal Disorders
Pharmacogenomics and Precision Medicine
Adverse Drug Reactions, Drug Interactions, and Toxicology
Prescriptive Authority, Legal-Ethical Considerations, and Evidence-Based Prescribing
Introduction
This comprehensive assessment evaluates the advanced pharmacotherapeutic knowledge and clinical reasoning
required for graduate-level nursing practice. The examination tests the candidate's ability to apply the principles of
pharmacokinetics, pharmacodynamics, and pharmacogenomics to the safe and effective prescribing of
medications across the lifespan. Using a rigorous multiple-choice and scenario-based format, this assessment
challenges the learner to analyze complex patient cases, interpret laboratory and genetic data, and make
evidence-based clinical decisions regarding drug selection, dosing, and monitoring. Success requires mastery of
,advanced pharmacology, critical thinking, and integration of ethical and legal standards to optimize therapeutic
outcomes and minimize adverse events in diverse patient populations.
SECTION ONE: Questions 1–100
Question 1
A 68-year-old patient with a history of heart failure with reduced ejection fraction (HFrEF) is prescribed
metoprolol succinate. What is the primary mechanism by which this beta-blocker improves morbidity and
mortality in heart failure?
A. Increasing cardiac contractility through beta-1 receptor stimulation.
B. Blocking the toxic effects of excessive sympathetic nervous system activation on the myocardium, thereby
reducing myocardial oxygen demand and preventing cardiac remodeling.
C. Acting as a potent vasodilator to decrease afterload.
D. Directly inhibiting the renin-angiotensin-aldosterone system (RAAS).
🟢 Correct Answer:
B
🔴 RATIONALE:
In HFrEF, chronic activation of the sympathetic nervous system (SNS) leads to elevated levels of catecholamines,
which are directly toxic to the myocardium. They increase heart rate, contractility, and afterload, which worsens
cardiac remodeling and apoptosis. Beta-blockers like metoprolol succinate (a beta-1 selective blocker) inhibit
these toxic effects by blocking cardiac beta-1 receptors. This reduces heart rate, decreases myocardial oxygen
demand, and slows the progression of ventricular remodeling. They do not increase contractility or directly
inhibit the RAAS.
,Question 2
A nurse practitioner is prescribing levothyroxine for a 55-year-old patient newly diagnosed with
hypothyroidism. What is the most important teaching point regarding the timing of administration?
A. "Take this medication with a full meal to prevent gastric irritation."
B. "Take this medication at bedtime to align with your circadian rhythm."
C. "Take this medication on an empty stomach, first thing in the morning, at least 30 to 60 minutes before
breakfast."
D. "Take this medication with a calcium supplement to improve absorption."
🟢 Correct Answer:
C
🔴 RATIONALE:
Levothyroxine absorption is significantly impaired by food, particularly fiber, soy, and certain minerals like
calcium and iron. To achieve consistent, therapeutic blood levels, levothyroxine must be taken on an empty
stomach, ideally first thing in the morning, and the patient must wait 30 to 60 minutes before eating or drinking
anything other than water. Taking it with food or supplements drastically reduces bioavailability and can lead to
inadequate treatment of hypothyroidism.
Question 3
A patient with atrial fibrillation is on long-term warfarin therapy. The provider is considering adding
trimethoprim-sulfamethoxazole (TMP-SMX) for an acute urinary tract infection. What is the primary concern
regarding this drug combination?
A. TMP-SMX decreases the absorption of warfarin, reducing its anticoagulant effect.
B. TMP-SMX is a potent inhibitor of the CYP2C9 enzyme, which metabolizes the S-isomer of warfarin, leading to
a significant increase in the international normalized ratio (INR) and bleeding risk.
, C. Warfarin induces the metabolism of TMP-SMX, rendering the antibiotic ineffective.
D. There is no significant interaction between these two medications.
🟢 Correct Answer:
B
🔴 RATIONALE:
Warfarin is a racemic mixture of R and S isomers, with the S-isomer being 2.5 to 5 times more potent. The S-
isomer is primarily metabolized by the hepatic CYP2C9 enzyme. TMP-SMX is a known, potent inhibitor of
CYP2C9. Co-administration leads to inhibition of warfarin metabolism, causing a rapid and dangerous rise in the
INR and a significant risk of major hemorrhage. If this combination is unavoidable, the warfarin dose must be
preemptively reduced by 20-50% and the INR monitored extremely closely.
Question 4
A 72-year-old patient with chronic renal insufficiency (estimated glomerular filtration rate [eGFR] of 28 mL/min)
requires anticoagulation for a newly diagnosed deep vein thrombosis. The provider selects enoxaparin. What
adjustment to the treatment plan is essential?
A. No adjustment is needed; renal function does not affect enoxaparin dosing.
B. The dose of enoxaparin must be reduced, as low molecular weight heparins are primarily cleared renally and
accumulate in renal impairment, increasing the risk of major bleeding.
C. The frequency of enoxaparin must be increased to twice-daily dosing.
D. Enoxaparin is absolutely contraindicated at any eGFR below 60 mL/min.
🟢 Correct Answer:
B
🔴 RATIONALE:
Low molecular weight heparins (LMWHs) like enoxaparin are cleared primarily by the kidneys. In patients with
significant renal impairment (typically an eGFR less than 30 mL/min), the drug accumulates, leading to a
